GIP / GLP1 co-agonist compounds

MY215891AActive Publication Date: 2026-10-29ELI LILLY & CO

0 Cites 0 Cited by

Patent Information

Application Number: MYPI2022006535
Authority / Receiving Office: MY · MY
Patent Type: Patents
Current Assignee / Owner
Filing Date: 2019-07-22
Publication Date: 2026-10-29
Estimated Expiration: 2039-07-22

Application Information

Patent Timeline

22 Jul 2019

Application

MYPI2022006535

29 Oct 2026

Publication

MY215891A

IPC: C07K14/605; A61K38/00; A61K38/26; A61P3/04; A61P3/10; C07K14/575

Inventors: ABRAHAM, MILATA MARY; ABURUB, AKTHAM

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. Compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). Also, the compounds may be useful in the treatment of obesity.

Need to check novelty before this filing date? Find Prior Art

Explore free tools for quick IP tasks

Patent Information

Abstract